ADX-097

Phase 2Withdrawn

0 views this week 0 watching💤 Quiet

Interest: 17/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

IgA Nephropathy

Conditions

IgA Nephropathy, Lupus Nephritis (LN), C3 (Complement Component 3) Glomerulopathy

Trial Timeline

Jun 27, 2024 → Jun 1, 2026

NCT ID

NCT06419205

About ADX-097

ADX-097 is a phase 2 stage product being developed by Q32 Bio for IgA Nephropathy. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT06419205. Target conditions include IgA Nephropathy, Lupus Nephritis (LN), C3 (Complement Component 3) Glomerulopathy.

What happened to similar drugs?

6 of 20 similar drugs in IgA Nephropathy were approved

Approved (6) Terminated (3) Active (11)

✅Anplag(Sarpogrelate) + PlaceboYuhanApproved

🔄olmesartan medoxomil + Placebo TabletsDaiichi SankyoPhase 3

❌Rituximab + cyclosporineSun PharmaceuticalPhase 3

❌Atrasentan + PlaceboAbbViePhase 3

✅Candesartan Cilexetil + Candesartan Cilexetil + Candesartan Cilexetil 32mgAstraZenecaApproved

🔄BION-1301 + PlaceboNovartisPhase 3

✅CyclosporineNovartisApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06419205	Phase 2	Withdrawn	Jun 27, 2024	Jun 1, 2026	IgA Nephropathy

Competing Products

20 competing products in IgA Nephropathy

See all competitors

Product	Company	Stage	Hype Score
Anplag(Sarpogrelate) + Placebo	Yuhan	Approved	43
CS-3150 + placebo	Daiichi Sankyo	Phase 2	35
olmesartan medoxomil + Placebo Tablets	Daiichi Sankyo	Phase 3	40
Beraprost sodium	Astellas Pharma	Pre-clinical	22
Tacrolimus + Placebo	Astellas Pharma	Phase 2	35
Rituximab + cyclosporine	Sun Pharmaceutical	Phase 3	32
Placebo + LY3016859	Eli Lilly	Phase 1/2	32
Dipeptidyl-Peptidase IV Inhibitors + Glucagon-Like Peptide 1	Eli Lilly	Pre-clinical	26
HR19042 Capsules + Placebo	Jiangsu Hengrui Medicine	Phase 2	35
HR19042 Capsule, Tarpeyo®, Budenofalk®	Jiangsu Hengrui Medicine	Phase 1	29
HR19042 capsule	Jiangsu Hengrui Medicine	Phase 1	29
Atrasentan + Placebo	AbbVie	Phase 3	32
Atrasentan	AbbVie	Phase 2	35
Candesartan Cilexetil + Candesartan Cilexetil + Candesartan Cilexetil 32mg	AstraZeneca	Approved	43
ALXN1920 + Placebo	AstraZeneca	Phase 2	42
Candesartan	AstraZeneca	Pre-clinical	26
Placebo + Atacicept 25 mg + Atacicept 75 mg	Merck	Phase 2	27
BION-1301 + Placebo	Novartis	Phase 3	44
MAU868 + Placebo	Novartis	Phase 2	27
Atrasentan	Novartis	Phase 2	39